Declared bankruptcy in Oct 2023
Company logo

NBRV - Nabriva Therapeutics plc

NASDAQ -> Healthcare -> Biotechnology
Dublin, Ireland
Type: Equity

NBRV price evolution
NBRV
(in millions $) 31 Mar 2023 31 Dec 2022 30 Sep 2022 30 Jun 2022
Current assets
Cash $1.92 $12.54 $14.77 $20.16
Short term investments
Net receivables $10.51 $6.74 $12.39 $12.36
Inventory $9.03 $9.68 $17.33 $15.54
Total current assets $23.69 $31.1 $47.56 $54.3
Long term investments
Property, plant & equipment $0.26 $0.28 $0.29 $0.21
Goodwill & intangible assets $0 $0 $0.01 $0.01
Total noncurrent assets $0.64 $0.66 $0.68 $0.6
Total investments
Total assets $24.34 $31.77 $48.24 $54.89
Current liabilities
Accounts payable $6.98 $5.43 $3.9 $1.07
Deferred revenue
Short long term debt $0.2 $4.83 $5.73 $6.62
Total current liabilities $28 $27.61 $21.64 $19.33
Long term debt $0.34 $0.39 $0.4 $0.51
Total noncurrent liabilities $0.7 $0.87 $0.98 $0.96
Total debt $0.54 $5.22 $6.13 $7.14
Total liabilities $28.7 $28.47 $22.62 $20.29
Shareholders' equity
Retained earnings -$661.56 -$652.86 -$630.08 -$618.57
Other shareholder equity $0.03 $0.03 $0.03 $0.03
Total shareholder equity -$4.36 $3.29 $25.62 $34.6
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $12.54 $47.83 $41.59 $86.41
Short term investments $0.02 $0.02 $0.17
Net receivables $6.74 $12.75 $4.28 $3.12
Inventory $9.68 $14.51 $5.82 $0.68
Total current assets $31.1 $80.27 $57.22 $91.17
Long term investments
Property, plant & equipment $0.28 $0.23 $0.77 $2.47
Goodwill & intangible assets $0 $0.03 $0.08 $0.09
Total noncurrent assets $0.66 $0.64 $1.22 $2.94
Total investments $0.02 $0.02 $0.17
Total assets $31.77 $80.91 $58.44 $94.11
Current liabilities
Accounts payable $5.43 $4.37 $2.89 $4.67
Deferred revenue $0.37 $0.75
Short long term debt $4.83 $3.77 $2.04
Total current liabilities $27.61 $22.34 $18.52 $16.64
Long term debt $0.39 $4.26 $5.69 $34.5
Total noncurrent liabilities $0.87 $5.22 $6.78 $36.2
Total debt $5.22 $8.03 $7.73 $34.5
Total liabilities $28.47 $27.56 $25.3 $52.84
Shareholders' equity
Retained earnings -$652.86 -$595.68 -$546.23 -$476.74
Other shareholder equity $0.03 $0.03 $0.03 $0.03
Total shareholder equity $3.29 $53.35 $33.13 $41.27
(in millions $) 31 Mar 2023 31 Dec 2022 30 Sep 2022 30 Jun 2022
Revenue
Total revenue $7.59 $10.57 $9.15 $9.19
Cost of revenue $4.44 $16.35 $4.42 $4.46
Gross Profit $3.15 -$5.78 $4.74 $4.74
Operating activities
Research & development $2.63 $2.63 $4.03 $4.09
Selling, general & administrative $9 $9.61 $11.91 $11.05
Total operating expenses $11.63 $12.24 $15.94 $15.13
Operating income -$8.47 -$18.01 -$11.2 -$10.4
Income from continuing operations
EBIT -$8.51 -$22.33 -$10.85 -$10.49
Income tax expense $0.31 $0.52 $0.39
Interest expense $0.19 $0.14 $0.15 $0.2
Net income
Net income -$8.7 -$22.78 -$11.51 -$11.07
Income (for common shares) -$8.7 -$22.78 -$11.51 -$11.07
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue $36.94 $28.89 $5.03 $9.48
Cost of revenue $28.58 $13.15 $0.77 $0.07
Gross Profit $8.35 $15.75 $4.26 $9.41
Operating activities
Research & development $14.26 $12.63 $15.1 $26.41
Selling, general & administrative $45.26 $51.65 $55.28 $62.48
Total operating expenses $59.53 $64.28 $70.39 $88.9
Operating income -$51.17 -$48.53 -$66.13 -$79.49
Income from continuing operations
EBIT -$54.92 -$48.06 -$67.61 -$79.02
Income tax expense $1.57 $0.49 $0.14 $0.1
Interest expense $0.7 $0.9 $1.74 $3.64
Net income
Net income -$57.19 -$49.45 -$69.48 -$82.76
Income (for common shares) -$57.19 -$49.45 -$69.48 -$82.76
(in millions $) 31 Mar 2023 31 Dec 2022 30 Sep 2022 30 Jun 2022
Net income -$8.7 -$22.78 -$11.51 -$11.07
Operating activities
Depreciation $0.02 $0.03 $0.04 $0.08
Business acquisitions & disposals
Stock-based compensation $1 $0.14 $0.5 $0.33
Total cash flows from operations -$5.62 -$1.63 -$6.18 -$13.04
Investing activities
Capital expenditures -$0 -$0.01 -$0.1 -$0.06
Investments
Total cash flows from investing -$0 -$0.01 -$0.1 -$0.12
Financing activities
Dividends paid
Sale and purchase of stock $0.08 $0.4
Net borrowings -$4.85 -$0.62 $1.11 -$0.55
Total cash flows from financing -$4.85 -$0.66 $1.11 -$0.79
Effect of exchange rate -$0.14 $0.06 -$0.22 $0.15
Change in cash and equivalents -$10.62 -$2.23 -$5.39 -$13.79
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income -$57.19 -$49.45 -$69.48 -$82.76
Operating activities
Depreciation $0.22 $0.36 $0.82 $0.77
Business acquisitions & disposals
Stock-based compensation $1.97 $3.29 $5.22 $9.75
Total cash flows from operations -$36.71 -$59.56 -$71.33 -$71.89
Investing activities
Capital expenditures -$0.21 -$0.03 -$0.11 -$0.06
Investments
Total cash flows from investing -$0.26 -$0.08 -$0.27 $0.33
Financing activities
Dividends paid
Sale and purchase of stock $2.12 $27.91 $54.17 $20.51
Net borrowings $0.54 $42.28 -$22.48 $37.92
Total cash flows from financing $1.85 $66.37 $26.92 $56.08
Effect of exchange rate -$0.17 -$0.48 -$0.14 -$0.11
Change in cash and equivalents -$35.3 $6.24 -$44.82 -$15.59
Fundamentals
Market cap $1.28M
Enterprise value -$98.40K
Shares outstanding 3.20M
Revenue $36.51M
EBITDA -$52.02M
EBIT -$52.17M
Net Income -$54.07M
Revenue Q/Q -5.36%
Revenue Y/Y 6.16%
P/E ratio -0.02
EV/Sales -0.00
EV/EBITDA 0.00
EV/EBIT 0.00
P/S ratio 0.04
P/B ratio -0.29
Book/Share -1.37
Cash/Share 0.60
EPS -$16.89
ROA -135.81%
ROE -365.53%
Debt/Equity 8.65
Net debt/EBITDA -0.51
Current ratio 0.85
Quick ratio 0.52